Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2006, p. 441-448, Vol. 44, No. 2
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.2.441-448.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
dem H. Williams,1
Sami Oikarinen,2
Sisko Tauriainen,2
Kimmo Salminen,3
Heikki Hyöty,2,4 and
Glyn Stanway1*
Department of Biological Sciences, University of Essex, Colchester, CO4 3SQ, United Kingdom,1 JDRF Centre for Prevention of Type 1 Diabetes in Finland, Department of Virology, University of Tampere, Medical School, Tampere, Finland,2 Department of Virology, University of Turku and Turku City Hospital, Turku, Finland,3 Centre of Laboratory Medicine, Tampere University Hospital, Tampere, Finland4
Received 9 December 2004/ Returned for modification 25 April 2005/ Accepted 1 November 2005
|
|
|---|
|
|
|---|
For more than 100 years, viruses have been suspected to be a factor in the etiology of type 1 diabetes mellitus (T1D) (15), and most reports have concerned the involvement of enteroviruses, frequently the HEV-B species members and CBVs (18). Viruses seem to be involved in the triggering of an autoimmune reaction, which subsequently leads to the destruction of islet cells. Over the past few years, a number of studies have reported an association between enteroviruses and diabetes on the basis of reverse transcription (RT)-PCR amplification from clinical material, using specific sequences from the well-conserved 5' UTR (1, 8, 10). However, these studies have provided limited information on the precise nature of the enterovirus present, as frequent recombination means that 5'-UTR sequences do not correlate with other regions of the genome, notably, the capsid-encoding region, which determines the serotype and receptor binding properties of the virus (19, 25, 27, 39, 44). Virus propagation from diabetic subjects has been another approach. CBV4 and E9 strains isolated in this way have been studied, and attempts to identify diabetic determinants have been made (21, 37, 48, 52). Other studies have identified sequences in enteroviruses that could be involved in autoimmunity through molecular mimicry (13, 14, 36, 53). Recently, enterovirus RNA has been demonstrated in islet cells of some diabetic patients, and these cells were shown to express several receptors recognized by enteroviruses (55). In addition, work on a strain of CBV4 indicated that changes close to the canyon, the site of receptor binding in enteroviruses, correlated with persistent infection in pancreatic islet cells, emphasizing a potential role for receptor interactions in T1D (54). However, our understanding of the role of enteroviruses in diabetes and potential molecular determinants is still very incomplete.
During a prospective study of T1D, the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, an enterovirus was isolated from an individual who soon after virus isolation developed a range of typical autoantibodies seen in diabetic and prediabetic subjects, although to date the patient has not developed clinical T1D. This is the first description of such an enterovirus strain being isolated at the time when the beta-cell damage process starts, and thus, it can provide new information about the role of enteroviruses in these early stages of pathogenesis. The virus proved to be a strain of echovirus 3 (E3), and as there were limited sequence data available for this serotype, we obtained the complete nucleotide sequence of the isolate. Here, we show that the virus differs significantly from the E3 prototype, Morrisey, but is very similar to other recently circulating strains.
|
|
|---|
*02, *0301, or *0602], and also boys with the genotype DQB1*02/y-DQA1*05/z [y
*0301, *0302, *0602, *0603; z
*0201] are observed from birth. The protocol was described in detail previously (24). Serum samples are collected from birth at intervals of 3 to 6 months to test for the possible appearance of diabetes-associated autoantibodies, including islet cell autoantibodies (ICA) and insulin autoantibodies (IAA), as well as autoantibodies (GADA) against the 65-kDa isoform of glutamic acid decarboxylase (GAD65) and protein tyrosine phosphatase-related IA-2 molecule (IA-2A). The clinical symptoms are recorded every visit using a questionnaire. Serum samples are also used for virus analyses. In addition, stool samples are collected every month from the age of 3 months for virus isolation. Patient and virus isolation. The patient was born on 3 February 1998, and he was recruited into the study. He had increased genetic risk of developing T1D, as he carried the DR4/DQ8 haplotype. He had normal diet and weight/height gain and had no chronic diseases, allergies, or first-degree relatives with T1D or other autoimmune diseases. The isolation was done from a stool sample collected at the age of 6.5 months (on 19 August 1998). The child is still in follow-up, the latest examination being at the age of 7 years and 1 month (on 3 March 2005). He has remained consistently positive for diabetes-associated autoantibodies but has not yet developed T1D. Virus in the stool sample, termed PicoBank/DM1/E3, was cultured in CaCo-2 (human colon carcinoma) cells using methods previously described (43).
Measurement of neutralizing antibodies. Serotype-specific antibodies against the isolated E3 strain (PicoBank/DM1/E3) were measured in the serial serum samples of this child, using the standard plaque neutralization assay as previously described (40). The green monkey kidney (GMK) cell line used was purchased from the American Type Culture Collection. Serum was incubated in two different dilutions (1/16 and 1/64) with the virus (100 PFU) for 1 h at 36°C. Then, the samples were applied to GMK cell monolayers grown in six-well plates (Nunclon; NUNC, Denmark) and further incubated at 36°C for 48 h. The amount of infectious virus was measured by counting the plaques; the reciprocal of the last serum dilution able to block virus infectivity by 80% was taken as the titer of neutralizing antibodies. A fourfold or greater increase in antibody titer between two follow-up samples was considered significant, indicating acute infection.
Extraction of RNA from a cultured clinical sample and RT-PCR. RNA was extracted from 100 µl of the tissue culture supernatant from infected CaCo-2 cells, using a Nucleospin RNA II extraction kit (Macherey Nagel) according to the manufacturer's instructions. The RNA was resuspended in 60 µl of nuclease-free water, and 5 µl was then subjected to one-step RT-PCR by the use of a SuperScript One-Step RT-PCR kit (Invitrogen) and primers designed specifically for the detection of members of the HEV-B species of enteroviruses (Table 1).
|
View this table: [in a new window] |
TABLE 1. Sequences of general primers for the amplification of the genomes of HEV-B members
|
Determination and analysis of the complete genome sequence of PicoBank/DM1/E3. The primer sequences were removed, and the overlapping sequences were assembled into a contiguous sequence. Sequence alignments were carried out by the use of ClustalW (51; http://www.ebi.ac.uk/clustalw/index.html). For phylogenetic analysis, sequences were aligned by using ClustalW and jalview to introduce gaps where necessary. The neighbor-joining algorithm implemented in the ClustalX software (50) was used to generate trees, which were bootstrapped 1,000 times. The trees were drawn using the NJPLOT software (38).
The following complete enterovirus sequences (accession numbers are in parentheses) were used in the construction of phylogenetic trees: CBV1 Japan (M16560), CBV2 Ohio (AF085363), CBV3 Nancy (M88483), CBV4 JVB (X05690), CBV4-D (E2 variantAF311939) CBV5 Faulkner (AF114383), CBV6 Schmitt (AF105342), swine vesicular disease virus UKG/27/72 (X54521), CAV9 Griggs (D00627), E1 Farouk (AF029859), E2 Cornelis (AY302545), E3 Morrisey (AY302553), E4 Pesacek (AY302557), E5 Noyce (AF083069), E6 Charles (U16283), E6 D'Amori (AY302558), E7 Wallace (AY302559), E9-Hill (X84981), E9-BartyINF (AF524866), E9-DM (AF524867), E11 Gregory (X80059), E11-Kar/87 (AY167104), E12 Travis (X79047), E13 Del Carmen (AY302539), E14 Tow (AY302540), E15 Ch 96-51 (AY302541), E16 Harrington (AY302542), E17 CHHE-29 (AY302543), E18 Metcalf (AF317694), E19 Burke (AY302544), E20 JV-1 (AY302546), E21 Farina (AY302547), E24 DeCamp (AY302548), E25 JV-4 (AY302549), E26 Coronel (AY302550), E27 Bacon (AY302551), E29 JV-10 (AY302552), E30 Bastianni (AF311938), E31 Caldwell (AY302554), E32 PR-10 (AY302555), E33 Toluca-3 (AY302556), EV69 Toluca-1 (AY302560), EV73 CA55-1988 (AF241359), and EV77 CF496-99 (AJ493062). Partial sequences from the following E3 isolates, whose countries of isolation and accession numbers are given in parentheses, were also used: W178-128/99 (France; AY208114), 94CF858 (France; AJ241446), mo/Roma98 (Italy; AJ309243), si/Roma97 (Italy; AJ309242), 810/85 (Sweden; AF295490), 2392-82 (Sweden; AF295453), 1446-81 (Sweden; AF295439), Morrisey (United States; AF081316), and MD86-6393 (United States; AF152264).
Nucleotide sequence accession data. The complete nucleotide sequence of PicoBank/DM1/E3 reported in this paper has been deposited in the GenBank database under the accession number AJ849942.
|
|
|---|
![]() View larger version (15K): [in a new window] |
FIG. 1. Autoantibody levels, neutralizing antibody titer against the isolated PicoBank/DM1/E3 strain (top), and viral RNA detected using enterovirus-specific RT-PCR in stool samples during the follow-up of the child participating in the DIPP study. The subject turned autoantibody positive (IAA) at the age of 9 months (marked by a vertical arrow). He had two enterovirus RNA-positive stool samples during the follow-up. The virus isolation was done from a stool sample collected at the age of 6.5 months. E3, PicoBank/DM1/E3 strain. The units of autoantibody levels were as follows: ICA ( ), JDF-U; GADA (), RU; IAA ( ), RU; and IA-2A ( ), RU.
|
Sequence. Partial sequence analysis of the virus (PicoBank/DM1/E3) propagated from the stool sample suggested that it is a HEV-B species member. By comparing enterovirus sequences, we have developed primers with the potential to amplify the whole genome from all HEV-B members in six overlapping fragments, using RT-PCR (Table 1). Each of these fragments was generated from the isolate, and the fragments were sequenced in both orientations. The derived sequence is 7,427 nucleotides long, including nucleotides 1 to 20, which were used as the priming site for the 5'-UTR PCR primer (and thus not determined), plus the poly(A) tract.
Relationship of PicoBank/DM1/E3 to other enteroviruses. A dendrogram representing the relationship between the amino acid sequences of the P1 regions of all HEV-B members (35) indicates that PicoBank/DM1/E3 clusters with the E3 prototype strain Morrisey (Fig. 2a). It has 95% amino acid identity to E3-Morrisey in VP1 (data not shown), well within the identity range seen in an enterovirus serotype, suggesting strongly that it is a member of the E3 serotype (33, 34). In contrast, the 2C-plus-3CD region, also used regularly for the analysis of picornavirus phylogeny, showed no clear linkage to E3-Morrisey (Fig. 2b). We used the nucleotide sequence for this analysis, as HEV-B amino acid sequences are very similar. In this region, the closest relative of PicoBank/DM1/E3 is Kar/87, an E11 isolate, but it is only marginally more similar to this isolate than to a range of other sequenced enteroviruses. To study this disparity between the P1 and 2C-plus-3CD regions further, graphs of nucleotide sequence identity across the genome, compared with a selection of other enteroviruses, were plotted (Fig. 3). These confirmed that PicoBank/DM1/E3 and E3-Morrisey are closely related throughout the capsid region. However, downstream of the P1/P2 junction, E3-Morrisey is highly similar to the E6 prototype, Charles, while PicoBank/DM1/E3 is much less closely related, providing evidence that at least one of the two E3 strains has undergone a recombination event during divergence. There are also significant differences between the E3 strains in the 5' UTR (data not shown).
![]() View larger version (22K): [in a new window] |
FIG. 2. Phylogenetic trees expressing the relationship between HEV-B members in different regions of the genome. The trees were derived using the N-J method in the ClustalX software and were bootstrapped 1,000 times before being plotted using the NJPLOT software. Bootstrap values (%) are shown on the branches. (a) Amino acid sequence of P1. (b) Nucleotide sequence of 2C plus 3CD.
|
![]() View larger version (23K): [in a new window] |
FIG. 3. Nucleotide sequence identities across the genome between E3-Morrisey and a range of enteroviruses, including PicoBank/DM1/E3, together with a schematic representation of the enterovirus genome. The enteroviruses selected are the closest relatives of the two E3 strains. E6, E9, and E12 are prototype strains, and E11-Kar/87 is a recent E11 isolate. SVDV, swine vesicular disease virus. A window of 300 nucleotides and steps of 60 nucleotides were used.
|
![]() View larger version (18K): [in a new window] |
FIG. 4. Phylogenetic tree expressing the relationship between PicoBank/DM1/E3 and other E3 isolates (W178-128/99, 94CF858, mo/Roma98, si/Roma97, 810/85, 2392-82, 1446-81, Morrisey, and MD86-6393) based on nucleotide identity in part of VP1 (nucleotides 2573 to 2874). Bootstrap values (%) are shown on the branches.
|
Previous analyses of enterovirus sequences (partial 5' UTR) found in the blood of patients presenting with T1D indicated that they were related to CBV3 and CBV4 (1, 10). Comparisons of PicoBank/DM1/E3 with these sequences (10) indicate no clear grouping (Fig. 5), in common with comparisons with sequences (1) from adult patients (data not shown). Additionally, the PicoBank/DM1/E3 sequence does not add weight to the importance of 5'-UTR residues highlighted by these previous studies on the basis of differences between the prototypes and clinical isolates. Positions 229, 234, and 303, identified in these studies, are identical in E3-Morrisey and PicoBank/DM1/E3. The diabetogenic E9 isolate DM (E9-DM) also does not differ from the E9 prototype, Barty (E9-Barty INF), at these positions (37).
![]() View larger version (19K): [in a new window] |
FIG. 5. Molecular relationships in part of the 5' UTR (nucleotides 150 to 448 in CBV3-Nancy) between previously reported enterovirus sequences from juvenile diabetic patients (10) and potentially diabetogenic E3, E9, and CBV4 isolates, together with corresponding reference strains. The trees were plotted as for Fig. 2. Bootstrap values (%) are shown on the branches.
|
|
View this table: [in a new window] |
TABLE 2. Amino acid differences between PicoBank/DM1/E3 and E3-Morrisey in capsid regiona
|
|
|
|---|
E3 has been comparatively little studied, and in addition to the reference strain, there are very limited sequence data available for only 11 isolates. Thus, the present study greatly extends the molecular information available on this serotype. It is clear that E3 is a typical HEV-B member in terms of sequence (Fig. 2). It also conforms to the pattern seen in several recent reports of uncoupling of capsid region evolution from that of the 5' UTR and nonstructural region through frequent recombination (9, 25, 27, 44). E3-Morrisey is closely related to the E6 prototype, Charles, in the nonstructural region and much less so to PicoBank/DM1/E3 in this region (Fig. 3), suggesting recombination since the divergence of the lineages giving rise to E3-Morrisey and PicoBank/DM1/E3. The recombination point between the two E3 lineages seems to be close to the P1/P2 boundary, as seen in a number of other enteroviruses (27), as the lines representing the identity between E3-Morrisey and E6-Charles, and between E3-Morrisey and PicoBank/DM1/E3, cross over around position 3600 (Fig. 3). In nucleotide sequence identity terms (Fig. 3), the closest sequenced relative of PicoBank/DM1/E3 in the nonstructural region is a recent (1988) Russian isolate of E11 (Kar/87), supporting the suggestion that recombination may allow rapid exchange of nonstructural lineages between serotypes (27). In this case, it is likely that a recombination event has occurred in the 3CD region, as the PicoBank/DM1/E3/E11-Kar/87 identity increases sharply there (data not shown).
Previous molecular and serology studies have tended to implicate CBVs in diabetes, and the identification of PicoBank/DM1/E3 as an E3 isolate extends the range of enterovirus serotypes that may be involved in diabetes. A recent report describes the molecular and biological characterization of an E9 strain, E9-DM, shown to be diabetogenic, while patients infected during an E16 outbreak in Cuba were shown to develop autoantibodies characteristic of T1D (5, 37). Thus, there is growing evidence that echoviruses could be an environmental factor in T1D. As yet, no other echoviruses have been identified in the DIPP study, but this may be a reflection of the fact that few viruses have been successfully isolated at the time of autoantibody seroconversion.
The PicoBank/DM1/E3 sequence was examined for previously suggested correlates of diabetogenicity. In common with most other HEV-B members, it has the 2C and VP1 sequences previously implicated in autoimmunity and so could have a similar effect (4, 13, 14, 22, 53). More specific determinants of strains associated with diabetes have also been reported. A study of partial enterovirus 5'-UTR sequences detected in the blood of children presenting with T1D indicated that they were related to CBV3 and CBV4 and clustered together (10). However, neither PicoBank/DM1/E3 nor the diabetogenic E9 isolate E9-DM clusters with these sequences (Fig. 5), and the same is also true when comparisons are made between sequences (1) from adult patients (data not shown). In addition, specific nucleotide differences between the sequences from blood and the CBV3 and CBV4 prototype strains are not seen in either PicoBank/DM1/E3 and E3-Morrisey comparisons or comparisons between E9-DM and the E9 prototype, Barty. It should be noted that the blood samples were geographically and temporally close in origin and that a limited region of the genome was analyzed. It may well be that the clustering seen is due to these factors rather than being a common feature of viruses linked to T1D. The whole-genome sequencing approach adopted here and in the E9 study (37) promises to be more useful in determining such common features.
Comparisons with E3-Morrisey do not reveal any clear candidates for sequence features of PicoBank/DM1/E3 that could be associated with autoantibody appearance. There is also no obvious link with work done on encephalomyocarditis virus, a member of the genus Cardiovirus of the family Picornaviridae, where the critical difference between diabetogenic and nondiabetogenic strains was mapped precisely to VP1 position 167 (3), as PicoBank/DM1/E3 shows no significant differences from E3-Morrisey and the recent European isolates in the corresponding region of VP1. However, when the capsid differences are positioned on a three-dimensional structure predicted using CAV9, another HEV-B member, as a model (16), several differences cluster around the threefold axis (data not shown). These include a difference immediately at the threefold axis, in a location analogous to one that brings about altered cell tropism in CAV9 (Ç. H. Williams and G. Stanway, unpublished data), and a difference at this position could influence the tropism of PicoBank/DM1/E3.
The patient from whom PicoBank/DM1/E3 was isolated has remained positive for IA-2A and ICA for 6 years, indicating an ongoing autoimmune process, although he has not yet developed clinical T1D. This virus strain, isolated immediately prior to the appearance of autoantibodies, is particularly interesting, as it may be involved in the initiation of the beta-cell-damaging process. This is the first time that such a strain has been isolated, and further biological studies should give important information. Mouse models and human islets have been widely used in previous studies and are logical approaches for future work, although both have limitations. It is not clear how well animal models reflect the diabetogenicity of enteroviruses in humans, as there are significant differences in pathology (2). In addition, there is no established mouse model for echovirus 3. The use of human islet cells is complicated by the observation that all enteroviruses seem to infect these cells, causing a wide range of alterations (apoptosis, necrosis, or changes in insulin secretion without clear damage), and which of these correlate with diabetogenicity is not clear (7, 41, 42, 49, 54). Thus, a range of models and additional enterovirus strains isolated during prospective studies and at the time of onset are required to further address the role of enteroviruses in T1D. The identification of consistent molecular features in such strains would be additional strong evidence of a role for enteroviruses in T1D and would provide a basis for strategies, such as vaccination, aimed at preventing the disease.
C.H.W., S.O., H.H., and G.S. are members of the VIRDIAB study group, whose other members provided helpful discussions. Other members of the VIRDIAB study group include Kaisa Anturamäki (University of Tampere, Tampere, Finland), Didier Hober (Service de Virologie CHRU Lille and UPRES EA, Université Lille, Lille, France), Bernadette Lucas (Service de Virologie CHRU Lille and UPRES EA, Université Lille, Lille, France), Peter Muir (King's College London and Health Protection Agency South West, United Kingdom), Keith Taylor (Queen Mary and Westfield College, London, United Kingdom), Christos S. Bartsocas (University of Athens, Athens, Greece), Andriani Gerasimidou-Vazeou (University of Athens, Athens, Greece), Evangelos Bozas (University of Athens, Athens, Greece), and Johnny Ludvigsson (University of Linköping, Linköping, Sweden).
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»